Relationship Between Body Weight and Glycohemoglobin
Relationship Between Changes in Body Weight and Glycohemoglobin Levels in Patients With Type 2 Diabetes Treated With Diet or Pioglitazone.
1 other identifier
observational
100
1 country
1
Brief Summary
Control of body weight (BW) is important to prevent and manage type 2 diabetes. Regardless of the close association, little is understood about the precise relationship between BW and glycemic control, which might be of benefit for patients with type 2 diabetes. The researchers investigated the correlation between changes in BW and glycemic control in patients with type 2 diabetes treated with a diet therapy or pioglitazone.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Apr 2009
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2009
CompletedFirst Submitted
Initial submission to the registry
May 1, 2009
CompletedFirst Posted
Study publicly available on registry
May 4, 2009
CompletedMay 4, 2009
May 1, 2009
Same day
May 1, 2009
May 1, 2009
Conditions
Keywords
Study Arms (2)
1 (type 2 diabetes, body weight, HbA1c)
The investigators analyzed the recorded data (body weight and glycohemoglobin) of 70 type 2 diabetic patients treated with the diet therapy. Recorded values at 0, 2 and 4 months for body weight (BW) and glycohemoglobin (HbA1c) were used. And changes from baseline (0 month) in BW (ΔBW) were plotted against those of HbA1c (ΔHbA1c).
2 (type 2 diabetes, pioglitazone, HbA1c)
The investigators analyzed the recorded data (body weight and glycohemoglobin) of 23 type 2 diabetic patients treated with pioglitazone. Recorded values at 0, 2 and 4 months for body weight (BW)and glycohemoglobin (HbA1c) were used. And changes from baseline (0 month) in BW (ΔBW) were plotted against those of HbA1c (ΔHbA1c).
Eligibility Criteria
primary care clinic
You may qualify if:
- type 2 diabetes under reasonable glycemic control (HbA1c; less than around 7%)
- type 2 diabetic patients treated with the diet therapy
You may not qualify if:
- type 2 diabetic patients with edema, severe liver dysfunction, renal dysfunction, moderate to severe anemia or congestive heart failure
- type 2 diabetic patients treated with insulin therapy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Department of Diabetes and Endocrinology, Saitama Medical Center, Saitama Medical University
Kawagoe, Saitama, 350-8550, Japan
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Eiji Ohmura, M.D.
Department of Diabetes and Endocrinology, Saitama Medical Center, Saitama Medical University
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
May 1, 2009
First Posted
May 4, 2009
Study Start
April 1, 2009
Primary Completion
April 1, 2009
Study Completion
April 1, 2009
Last Updated
May 4, 2009
Record last verified: 2009-05